prn facebook sharing logo

Pharmaceutical Leaders Pave the Way to New Alzheimer’s Treatments

Posted on
The price to the U.S. financial system from Alzheimer’s illness is estimated at $236 billion, together with the prices of caring for individuals with the illness. With out effective remedies, the financial influence will proceed to climb.

Whereas business behemoths like Pfizer and Novartis are apparent contenders, India Globalization Capital (IGC) is the primary cannabis pharmaceutical firm to concentrate on Alzheimer’s disease. While there are greater than a dozen publicly traded cannabis pharmaceutical stocks available on the market, most of them with market caps a lot bigger than IGC’s $12 million, IGC is up to now the one one to apply its cannabis-therapies to the remedy of Alzheimer’s.

IGC is aggressively advancing its distinctive position, and earlier this week announced ( that it has acquired the exclusive rights to a THC-based remedy for Alzheimer’s, shifting the corporate one step closer to medical trials for its Alzheimer’s product.

Beneath a definitive license settlement with the University of South Florida, IGC is the exclusive licensee of a patent filing for using tetrahydrocannabinol (THC) as a potential therapeutic agent for the disease. The patent, entitled “THC as a Potential Therapeutic Agent for Alzheimer’s Illness,” claims discovery of a brand new pathway through which low doses of THC bind to amyloid beta plaques and stop these plaques from aggregating on neurons, which is what happens in Alzheimer’s disease and causes cognitive decline.

This is why the appliance of TCH (tetrahydrocannabinol), which is the psychoactive compound present in cannabis, is so thrilling for the way forward for Alzheimer’s remedy. THC has a number of recognized molecular pathways by which it interacts with the physique. Quite a few research have shown that low doses of THC can sluggish the manufacturing of neural plaques (thought-about a key contributor to the progression of Alzheimer’s), as well as decrease inflammation, forestall cell dying and stimulate cell progress.

The acquisition of IGC’s new patent filing supplies one other layer of protection for the company’s proprietary formulation of IGC-AD1, which includes low-doses of THC and is intended to disrupt the buildup of amyloid beta plaques and relieve a number of the worst symptoms of Alzheimer’s.

If the patent is granted, and it really works, IGC will develop into the proprietor of a serious therapeutic pathway for THC interaction with the physique, with vital potential in treating this condition.

“Securing this licensing agreement from the College of South Florida represents a serious turning point for IGC as we now look to organize a number of of our key products for medical trials,” IGC CEO Ram Mukunda said within the press release. “We have now labored exhausting to assemble a robust improvement group and a main pipeline of 4 main merchandise addressing giant markets and potential blockbuster indications utilizing cannabis-based therapies. We’re putting the ending touches on our merchandise, which can embrace filing further patents, and we very a lot anticipate to start out pursuing medical trials for our Alzheimer’s product and others this yr.

IGC’s drug improvement pipeline also consists of cannabinoid remedy that targets human and veterinary epilepsy ( The corporate is creating numerous cannabis-based therapies, with a potential international market attain.

There are another corporations engaged on Alzheimer’s with very giant valuations, with IGC bringing the potential advantages of hashish to bear on the disease.

Biogen (NASDAQ: BIIB) has developed and tested aducanumab, a drug that helps remove beta amyloid, a sticky plaque discovered in the brain of Alzheimer’s patients. The antibody binds to the plaque, which has the potential to sluggish the development of symptoms reminiscent of memory loss, confusion, hassle discovering words, decreases in judgement, and modifications in temper and character. Part 1 medical trials included 165 sufferers, concluding that prime doses of the drug decreased the extent of amyloid plaque in the mind, as seen using positron emission tomography. Scientists noted the slowing of the development of memory loss in these patients as properly.

Other articles you might like;


,,dementia alzheimers,,alzheimers aducanumab clinical trial,,anavex life sciences,

Leave a Reply

Your email address will not be published. Required fields are marked *